Deepak Acharya1, Renzo Y Loyaga-Rendon2, Salpy V Pamboukian2, José A Tallaj2, William L Holman3, Ryan S Cantor4, David C Naftel3, James K Kirklin3. 1. Section of Advanced Heart Failure, Transplant, and Mechanical Circulatory Support, University of Alabama at Birmingham, Birmingham, Alabama. Electronic address: dacharya@uab.edu. 2. Section of Advanced Heart Failure, Transplant, and Mechanical Circulatory Support, University of Alabama at Birmingham, Birmingham, Alabama. 3. Division of Cardiovascular Surgery, University of Alabama at Birmingham, Birmingham, Alabama. 4. Division of Cardiovascular Surgery, University of Alabama at Birmingham, Birmingham, Alabama; Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama.
Abstract
BACKGROUND: Patients with acute myocardial infarction (AMI) complicated by acute heart failure or cardiogenic shock have high mortality with conventional management. OBJECTIVES: This study evaluated outcomes of patients with AMI who received durable ventricular assist devices (VAD). METHODS: Patients in the INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support) registry who underwent VAD placement in the setting of AMI were included and compared with patients who received VAD for non-AMI indications. RESULTS: VAD were implanted in 502 patients with AMI: 443 left ventricular assist devices; 33 biventricular assist devices; and 26 total artificial hearts. Median age was 58.3 years, and 77.1% were male. At implantation, 66% were INTERMACS profile 1. A higher proportion of AMI than non-AMI patients had pre-operative intra-aortic balloon pumps (57.6% vs. 25.3%; p < 0.01), intubation (58% vs. 8.3%; p < 0.01), extracorporeal membrane oxygenation (17.9% vs. 1.7%, p < 0.01), cardiac arrest (33.5% vs. 3.3%, p < 0.01), and higher-acuity INTERMACS profiles. At 1 month post-VAD, 91.8% of AMI patients were alive with ongoing device support, 7.2% had died on device, and 1% had been transplanted. At 1-year post-VAD, 52% of AMI patients were alive with ongoing device support, 25.7% had been transplanted, 1.6% had left VAD explanted for recovery, and 20.7% had died on device. The AMI group had higher unadjusted early phase hazard (hazard ratio [HR]: 1.24; p = 0.04) and reduced late-phase hazard of death (HR: 0.57; p = 0.04) than the non-AMI group did. After accounting for established risk factors, the AMI group no longer had higher early mortality hazard (HR: 0.89; p = 0.30), but it had lower late mortality hazard (HR: 0.55; p = 0.02). CONCLUSIONS: Patients with AMI who receive VAD have outcomes similar to other VAD populations, despite being more critically ill pre-implantation. VAD therapy is an effective strategy for patients with AMI and acute heart failure or shock in whom medical therapy is failing.
BACKGROUND:Patients with acute myocardial infarction (AMI) complicated by acute heart failure or cardiogenic shock have high mortality with conventional management. OBJECTIVES: This study evaluated outcomes of patients with AMI who received durable ventricular assist devices (VAD). METHODS:Patients in the INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support) registry who underwent VAD placement in the setting of AMI were included and compared with patients who received VAD for non-AMI indications. RESULTS: VAD were implanted in 502 patients with AMI: 443 left ventricular assist devices; 33 biventricular assist devices; and 26 total artificial hearts. Median age was 58.3 years, and 77.1% were male. At implantation, 66% were INTERMACS profile 1. A higher proportion of AMI than non-AMI patients had pre-operative intra-aortic balloon pumps (57.6% vs. 25.3%; p < 0.01), intubation (58% vs. 8.3%; p < 0.01), extracorporeal membrane oxygenation (17.9% vs. 1.7%, p < 0.01), cardiac arrest (33.5% vs. 3.3%, p < 0.01), and higher-acuity INTERMACS profiles. At 1 month post-VAD, 91.8% of AMI patients were alive with ongoing device support, 7.2% had died on device, and 1% had been transplanted. At 1-year post-VAD, 52% of AMI patients were alive with ongoing device support, 25.7% had been transplanted, 1.6% had left VAD explanted for recovery, and 20.7% had died on device. The AMI group had higher unadjusted early phase hazard (hazard ratio [HR]: 1.24; p = 0.04) and reduced late-phase hazard of death (HR: 0.57; p = 0.04) than the non-AMI group did. After accounting for established risk factors, the AMI group no longer had higher early mortality hazard (HR: 0.89; p = 0.30), but it had lower late mortality hazard (HR: 0.55; p = 0.02). CONCLUSIONS:Patients with AMI who receive VAD have outcomes similar to other VAD populations, despite being more critically ill pre-implantation. VAD therapy is an effective strategy for patients with AMI and acute heart failure or shock in whom medical therapy is failing.
Authors: F D Pagani; W Lynch; F Swaniker; D B Dyke; R Bartlett; T Koelling; M Moscucci; G M Deeb; S Bolling; H Monaghan; K D Aaronson Journal: Circulation Date: 1999-11-09 Impact factor: 29.690
Authors: Judith S Hochman; Lynn A Sleeper; John G Webb; Vladimir Dzavik; Christopher E Buller; Philip Aylward; Jacques Col; Harvey D White Journal: JAMA Date: 2006-06-07 Impact factor: 56.272
Authors: P Kellner; R Prondzinsky; L Pallmann; S Siegmann; S Unverzagt; H Lemm; S Dietz; J Soukup; K Werdan; M Buerke Journal: Med Klin Intensivmed Notfmed Date: 2013-04-06 Impact factor: 0.840
Authors: Karl Werdan; Martin Ruß; Michael Buerke; Georg Delle-Karth; Alexander Geppert; Friedrich A Schöndube Journal: Dtsch Arztebl Int Date: 2012-05-11 Impact factor: 5.594
Authors: Mandeep Singh; Jennifer White; David Hasdai; Patricia K Hodgson; Peter B Berger; Eric J Topol; Robert M Califf; David R Holmes Journal: J Am Coll Cardiol Date: 2007-10-30 Impact factor: 24.094
Authors: Lynne Warner Stevenson; Francis D Pagani; James B Young; Mariell Jessup; Leslie Miller; Robert L Kormos; David C Naftel; Karen Ulisney; Patrice Desvigne-Nickens; James K Kirklin Journal: J Heart Lung Transplant Date: 2009-06 Impact factor: 10.247
Authors: Alexandra E Sperry; Matthew Williams; Pavan Atluri; Wilson Y Szeto; Marisa Cevasco; Christian A Bermudez; Michael A Acker; Michael Ibrahim Journal: Curr Heart Fail Rep Date: 2021-05-06
Authors: Jeffrey B Washam; Babatunde Yerokun; Chetan B Patel; Ian J Welsby; Carmelo A Milano; Adam D DeVore Journal: J Thromb Thrombolysis Date: 2018-08 Impact factor: 2.300